Abstracts tagged "Interleukins (IL) and juvenile idiopathic arthritis (JIA)"

Abstract Number: 759 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis and Fever: Results From Two Pivotal Phase 3 Trials
Hermine Brunner¹, Nicolino Ruperto², Pierre Quartier³, Tamás Constantin⁴, Nico Wulffraat², Gerd Horneff⁵, Riva Brik⁶, Liza McCann⁷, Huri Ozdogan², Lidia Rutkowska-Sak⁷, Rayfel Schneider¹, Yackov Berkun⁸, Inmaculada Calvo⁵, Muferet Erguven⁷, Laurence Goffin⁷, Michael Hofer⁹, Tilmann Kallinich¹⁰, Karine Lheritier¹¹, Ken Abrams¹², Andrea Stancati¹¹, D. J. Lovell¹³ and Alberto Martini¹⁴, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, ²Paediatric Rheumatology International Trials Organisation (PRINTO)-Istituto Gaslini, Genova, Italy, ³Necker-Enfants Malades Hospital, Paris, France, ⁴Pediatric Rheumatology, University Childrens Hospital, Budapest, Hungary, ⁵PRINTO, Genoa, Italy, ⁶Pediatrics, Rambam Medical Center, Haifa, Israel, ⁷Paediatric Rheumatology International Trials Organization (PRINTO), Genova, Italy, ⁸Pediatrics, Hadassah Medical Center, Mount Scopus, Jerusalem, Israel, ⁹Centre Multisite Romand de Rhumatologie Pediatrique, Lausanne, Switzerland, ¹⁰Charite, University Medicine Berlin, Berlin, Germany, ¹¹Novartis Pharma AG, Basel, Switzerland, ¹²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹³Cincinnati Children's Hospital, Cincinnati, OH, ¹⁴Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH
Background/Purpose : Systemic juvenile idiopathic arthritis (sJIA) is an interleukin-1β (IL-1β)-mediated autoinflammatory disease. Canakinumab is a selective, fully human, anti-IL-1β monoclonal antibody. Two pivotal phase…
Abstract Number: 761 • 2012 ACR/ARHP Annual Meeting
Analysis of Biomarkers in Systemic Juvenile Idiopathic Arthritis Patients On Canakinumab Therapy
Nico Wulffraat¹, Hermine Brunner², Nicolino Ruperto³, Pierre Quartier⁴, Riva Brik⁵, Liza McCann⁵, Huri Ozdogan⁵, Lidia Rutkowska-Sak⁵, Rayfel Schneider², Valeria Gerloni⁵, Liora Harel⁶, Maria Hilário², Kristin Houghton², Rik Joos⁵, Daniel Kingsbury², Arndt Brachat⁷, Stephan Bek⁷, Martin Schumacher⁷, Marie-Anne Valentin⁸, N.R Nirmala⁹, Hermann Gram⁷, Ken Abrams¹⁰, Alberto Martini¹¹ and D. J. Lovell¹², ¹PRINTO, Genoa, Italy, ²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, ³Pediatric Rheumatology International Trials Organization (PRINTO)-Istituto Gaslini, Genova, Italy, ⁴Pediatria II, Istituto Giannina Gaslini, Genoa, Italy, ⁵Paediatric Rheumatology International Trials Organization (PRINTO), Genova, Italy, ⁶Pediatric Rheumatology unit, Schneider Children's Medical Center, Tel Aviv University, Petach Tikvah, Israel, ⁷Novartis Institutes for Biomedical Research, Basel, Switzerland, ⁸Biomarker Development, Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Institutes for Biomedical Research, Cambridge, MA, ¹⁰Novartis Pharmaceuticals Corporation, New Jersey, ¹¹Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ¹²Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) is a severe disabling subtype of Juvenile Idiopathic Arthritis characterized by arthritis plus systemic symptoms, such as high fever,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].